87642-31-7 Usage
Description
3-(4-FLUOROPHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINE is a heterocyclic chemical compound with a molecular formula C14H14FN3. It features a pyrazole ring and a pyridine ring, and the incorporation of a fluorophenyl group suggests it may engage in specific interactions with biological targets. 3-(4-FLUOROPHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINE holds potential pharmacological activity and is considered valuable for medicinal chemistry research, making it a promising candidate for drug discovery and development.
Uses
Used in Pharmaceutical Industry:
3-(4-FLUOROPHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINE is used as a lead compound for the development of new drugs due to its potential pharmacological activity and the possibility of specific interactions with biological targets, which can be harnessed to treat various diseases and conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3-(4-FLUOROPHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINE serves as a valuable chemical entity for studying its interactions with biological targets. This research can lead to a better understanding of its therapeutic potential and the optimization of its structure for improved efficacy and safety in drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 87642-31-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,7,6,4 and 2 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 87642-31:
(7*8)+(6*7)+(5*6)+(4*4)+(3*2)+(2*3)+(1*1)=157
157 % 10 = 7
So 87642-31-7 is a valid CAS Registry Number.
87642-31-7Relevant articles and documents
Ligand efficient tetrahydro-pyrazolopyridines as inhibitors of ERK2 kinase
Bagdanoff, Jeffrey T.,Jain, Rama,Han, Wooseok,Poon, Daniel,Lee, Patrick S.,Bellamacina, Cornelia,Lindvall, Mika
, p. 3626 - 3629 (2015)
Abstract A series of structure based drug design hypotheses and focused screening efforts drove improvements in the potency and lipophilic efficiency of tetrahydro-pyrazolopyridine based ERK2 inhibitors. Elaboration of a fragment chemical lead established
